Qures Group Ltd



what we want, but what we get today, from the available:

TREATMENTS FOR INFECTIONS

		Current	OSCEAUN®
			Potential
Effective		pass	pass
Fast acting -	Shorter stay in hospital	half	pass
Broad anti-pathogen efficacy		half	pass
Speed of Diagnosis	No delay for diagnosis	half	pass
Simple to deliver		pass	??
Resistance avoided No ABR No AMR No AFR No A			pass
Nature-identical		half	pass
Effective against bacterial infection		half	pass
Not harmful to friendly bacteria		fail	pass
Effective against fungal infection		fail	pass
Beneficial for Gut Microbiome No harm to comme		mensal ha	lf pass
In-vitro efficacy		half	pass
In-vivo efficacy		half	pass
Complements Immune system		fail	pass
Safe Harm	nless to human cells or DNA	half	pass
Harmless to Animal cells		half	pass
Harmless to Plant cells		half	pass
Safety	Absence of adverse effects	s half	pass
Cost effective		??	??

Score 6/20 19/20